This site is intended for healthcare professionals

Sanofi to acquire Origimm Biotechnology and with it novel therapeutic vaccine ORI-001 for acne vulgaris.

Read time: 1 mins
Last updated:3rd Dec 2021
Published:3rd Dec 2021
Sanofi announced that it entered into an agreement to acquire Origimm Biotechnology GmbH, an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease, such as acne.

With this acquisition, Sanofi continues executing its global Play to Win strategy, pursuing growth opportunities and building an industry-leading vaccines pipeline. The transaction will add ORI 001 to Sanofi’s early-stage pipeline. ORIm001 is a therapeutic vaccine candidate for acne vulgaris based on recombinant proteins, which entered preliminary clinical studies in Q3 2021. In parallel, Sanofi is working to develop additional antigen versions and expects to leverage its next-generation mRNA platform in a comprehensive Phase 1/II trial to start in 2023.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.